Staging of brain pathology related to sporadic Parkinson’s disease
The DOI matches its Crossref record; 70 of the 71 references it cites were found in a registry or an index.
Abstract
Sporadic Parkinson's disease involves multiple neuronal systems and results from changes developing in a few susceptible types of nerve cells. Essential for neuropathological diagnosis are alpha-synuclein-immunopositive Lewy neurites and Lewy bodies. The pathological process targets specific induction sites: lesions initially occur in the dorsal motor nucleus of the glossopharyngeal and vagal nerves and anterior olfactory nucleus. Thereafter, less vulnerable nuclear grays and cortical areas gradually become affected. The disease process in the brain stem pursues an ascending course with little interindividual variation. The pathology in the anterior olfactory nucleus makes fewer incursions into related areas than that developing in the brain stem. Cortical involvement ensues, beginning with the anteromedial temporal mesocortex. From there, the neocortex succumbs, commencing with high order sensory association and prefrontal areas. First order sensory association/premotor areas and primary sensory/motor fields then follow suit. This study traces the course of the pathology in incidental and symptomatic Parkinson cases proposing a staging procedure based upon the readily recognizable topographical extent of the lesions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, although α-syn appears early in peripheral tissues, brain damage in PD begins in the brainstem and spreads to the cortex [125,133,134,135].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [125]
In the citing paper
“The current understanding of PD pathogenesis suggests that a combination of genetic and environmental factors contributes to the progressive neurodegeneration of nigrostriatal dopaminergic neurons in the pars compacta of the substantia nigra, as well as other affected cortical regions [125,126].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [125]
In the citing paper
“robust evidence suggests that PD could start in the ENS and spread from there to the CNS via the vagal nerve [222,223].”
From Effects of Coffee and Its Components on the Gastrointestinal Tract and the Brain–Gut Axis (2020) · cites this paper as [222]
In the citing paper
“Braak et al. (2003) have mapped PD into six neuropathological disease stages.”
From The clinical symptoms of Parkinson's disease. (2016) · cites this paper as Braak et al. 2003
In the citing paper
“Early research on the neural mechanisms of anxiety in PD suggests that cingulate cortex alterations, associated with interoception deficit, could be a key point of anxiety pathophysiology and treatment24,25.”
From The experience of Anxiety for people with Parkinson’s disease (2023) · cites this paper as [24]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“The severity of co-occurring AD-related pathology was classified according to a procedure permitting differentiation of stages I–VI in the development of neurofibrillary changes and stages A–C in the evolution of -amyloid deposits (Table 2) [6,48].”
MethodSelf-citationParkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107 · cited 1×
“A: age, G: gender, nfp: neurofibrillary pathology, stages I–VI, a : stages of cortical –amyloid deposition A–C (0 = no AD-related lesions), PD: PD stages 1–6, clin: clinical diagnoses (−, no mention of PD symptoms in the clinical protocols, PD I–V: clinically diagnosed cases are indicated by PD and—if available—the Ho…”
BackgroundSome Methods for Strengthening the Common χ 2 Tests
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001616 · Cited by 3,718
Diagnostic Criteria for Parkinson Disease
Gelb, D. J., Oliver, E., & Gilman, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.1.33 · Cited by 2,822 · cited 1×
“The brain tissue exhibited nigral LBs and severe loss of nigral neuromelanin-laden neurons [16,30,37,62] (Fig.”
BackgroundThe substantia nigra of the human brain
Damier, P., Hirsch, E. C., Agid, Y., & Graybiel, A. M. (1999) · Brain · doi:10.1093/brain/122.8.1437 · Cited by 1,756 · cited 2×
“Damage to specific subnuclei of the substantia nigra, pars compacta, with severe obliteration of their neuromelaninladen projection neurons, frequently is considered to be the most important hallmark of PD [ 20 ,31,38,39,43].”
BackgroundResultFrequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656 · cited 1×
“The concomitant AD-related pathology lies within the expected range of the respective age groups [ 9 ].”
BackgroundSelf-citation(1998) · Europe PMC (PubMed Central) · Cited by 1,594
Paxinos, G., & Jürgen, K. (2004) · Cited by 1,478
Neuropathology of Parkinsonʼs Disease
Forno, L. S. (1996) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199603000-00001 · Cited by 1,465 · cited 1×
“A prerequisite for the postmortem diagnosis of both the presymptomatic and symptomatic phases of the pathological process underlying PD is evidence of specific inclusion bodies, which develop as spindle- or thread-like Lewy neurites (LNs) in cellular processes, and in the form of globular Lewy bodies (LBs) in neuronal…”
BackgroundCognitive deficits in Parkinson’s disease
Dubois, B., & Pillon, B. (1996) · Journal of Neurology · doi:10.1007/pl00007725 · Cited by 903 · cited 1×
“The damage incurred by important limbic structures (amygdala, hippocampal formation, anteromedial temporal mesocortex) as well as by extensive neocortical territories during stages 5–6 might well be considered to pave the way for declining intellectual faculties [14] and, in fact, impaired cognition is a frequent phen…”
BackgroundWhere Does Parkinson Disease Pathology Begin in the Brain?
Del Tredici, K., Rüb, U., de Vos, R. A. I., Bohl, J. R. E., & Braak, H. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.5.413 · Cited by 773
Self-citationMcKeith, I. G. (2004) · Europe PMC (PubMed Central) · Cited by 756
Pathoanatomy of Parkinson’s disease
Braak, H., & Braak, E. (2000) · Journal of Neurology · doi:10.1007/pl00007758 · Cited by 693 · cited 2×
“It is important to note that the somato-motor dysfunctions experienced by PD-patients—rather than solely reflecting a loss of dopaminergic neurons within the nigrostriatal system—may be traceable to extranigral impairment of the motor system [10,13].”
BackgroundSelf-citationPathology of Parkinson’s disease: Changes other than the nigrostriatal pathway
Jellinger, K. A. (1991) · Molecular and Chemical Neuropathology · doi:10.1007/bf03159935 · Cited by 684 · cited 1×
“Cases with severe damage usually show lesions reaching the neocortex [10,13,22,23,50,53,63].”
BackgroundMesholam, R. I., Moberg, P. J., Mahr, R. N., & Doty, R. L. (1998) · Archives of Neurology · doi:10.1001/archneur.55.1.84 · Cited by 643 · cited 1×
“According to some clinical studies, PD-patients frequently complain of an impaired sense of smell years prior to the appearance of somato-motor impairments [45,46,57,71].”
BackgroundCriteria for diagnosing Parkinson's disease
Calne, D. B., Snow, B. J., & Lee, C. (1992) · Annals of Neurology · doi:10.1002/ana.410320721 · Cited by 628 · cited 1×
“The brain tissue exhibited nigral LBs and severe loss of nigral neuromelanin-laden neurons [16,30,37,62] (Fig.”
BackgroundDemonstration of amyloid deposits and neurofibrillary changes in whole brain sections
Braak, H., & Braak, E. (1991) · Brain Pathology · doi:10.1111/j.1750-3639.1991.tb00661.x · Cited by 598 · cited 2×
“The hemispheres then were divided midsagittally, and one hemisphere from each case was embedded in polyethylene glycol (PEG 1000) [ 7 ] and sectioned perpendicular to the intercommissural (Forel’s) axis into uninterrupted series of 100m thick free-floating sections.”
MethodSelf-citationThe substantia nigra of the human brain
Damier, P., Hirsch, E. C., Agid, Y., & Graybiel, A. M. (1999) · Brain · doi:10.1093/brain/122.8.1421 · Cited by 578 · cited 1×
“The pars compacta of the substantia nigra is heterogeneously composed, which means that its neuronal constituents display regionally variable traits [5,19,43].”
BackgroundGibb, W. R., & Lees, A. J. (1991) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.54.5.388 · Cited by 574 · cited 1×
“Damage to specific subnuclei of the substantia nigra, pars compacta, with severe obliteration of their neuromelaninladen projection neurons, frequently is considered to be the most important hallmark of PD [20,31,38,39,43].”
BackgroundSynucleinopathies: Clinical and Pathological Implications
Galvin, J. E., Lee, V. M.-Y., & Trojanowski, J. Q. (2001) · Archives of Neurology · doi:10.1001/archneur.58.2.186 · Cited by 466 · cited 2×
“The brains of all of the incidental cases and of individuals with clinically overt sporadic PD display the presence of -synuclein-immunoreactive LNs and LBs while at the same time being free of intracytoplasmic inclusions related to non-PD -synucleinopathies [35,41].”
BackgroundOlfactory dysfunction in Parkinson's disease.
Hawkes, C. H., Shephard, B. C., & Daniel, S. E. (1997) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.62.5.436 · Cited by 396 · cited 1×
“According to some clinical studies, PD-patients frequently complain of an impaired sense of smell years prior to the appearance of somato-motor impairments [45,46,57,71].”
BackgroundPathology and Biology of the Lewy Body
Pollanen, M. S., Dickson, D. W., & Bergeron, C. (1993) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199305000-00001 · Cited by 396 · cited 1×
“A prerequisite for the postmortem diagnosis of both the presymptomatic and symptomatic phases of the pathological process underlying PD is evidence of specific inclusion bodies, which develop as spindle- or thread-like Lewy neurites (LNs) in cellular processes, and in the form of globular Lewy bodies (LBs) in neuronal…”
BackgroundIrizarry, M. C., Growdon, W., Gomez-isla, T., Newell, K., George, J. M., Clayton, D. F., & Hyman, B. T. (1998) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199804000-00005 · Cited by 394 · cited 2×
“for the non-lysosomal ATP-dependent breakdown of abnormal proteins, gradually transforms into virtually insoluble LNs or LBs [1,2,15,25,29,41, 49 ,67,70].”
BackgroundThe human entorhinal cortex: normal morphology and lamina-specific pathology in various diseases
Braak, H., & Braak, E. (1992) · Neuroscience Research · doi:10.1016/0168-0102(92)90014-4 · Cited by 339 · cited 2×
“The nerve cells scattered throughout the white matter below the temporal mesocortex sustain heavy damage (lamina cellularis profunda, [8]).”
BackgroundSelf-citationAmygdala pathology in Parkinson's disease
Braak, H., Braak, E., Yilmazer, D., de Vos, R. A. I., Jansen, E. N. H., Bohl, J., & Jellinger, K. (1994) · Acta Neuropathologica · doi:10.1007/bf00296485 · Cited by 295 · cited 1×
“amygdala, and the ventral claustrum [11].”
Self-citationDickson, D. W., Ruan, D., Crystal, H., Mark, M. H., Davies, P., Kress, Y., & Yen, S.-H. (1991) · Neurology · doi:10.1212/wnl.41.9.1402 · Cited by 295 · cited 1×
“The plexus of long LNs extending throughout the second sector of the Ammon’s horn [26,27] generally begins developing at stage 3 (Fig.”
BackgroundThe anterior olfactory nucleus in Parkinson's disease
Pearce, R. K. B., Hawkes, C. H., & Daniel, S. E. (1995) · Movement Disorders · doi:10.1002/mds.870100309 · Cited by 290 · cited 1×
“The most mildly affected cases usually display lesions in the dorsal IX/X motor nucleus and/or intermediate reticular zone and, frequently, in the anterior olfactory nucleus [58] (Table 2).”
BackgroundNeuropathology of synuclein aggregates: New insights into mechanisms of neurodegenerative diseases
Duda, J. E., Lee, V. M.-Y., & Trojanowski, J. Q. (2000) · Journal of Neuroscience Research · doi:10.1002/1097-4547(20000715)61:2<121::aid-jnr1>3.0.co;2-4 · Cited by 264
Trojanowski, J. Q., & Lee, V. M.-Y. (1998) · Archives of Neurology · doi:10.1001/archneur.55.2.151 · Cited by 254 · cited 1×
“for the non-lysosomal ATP-dependent breakdown of abnormal proteins, gradually transforms into virtually insoluble LNs or LBs [1,2,15,25,29,41,49, 67 ,70].”
BackgroundForno, L. S. (1969) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1969.tb01316.x · Cited by 215
Autonomic Dysfunction in Parkinson's Disease
Koike, Y., & Takahashi, A. (1997) · European Neurology · doi:10.1159/000113470 · Cited by 211
Paralysis agitans. I. Pathologische Anatomie
Lewy, F. (1912) · Medical Entomology and Zoology · Cited by 208
Autonomic dysfunction in Parkinson's disease
Goetz, C. G., Lutge, W., & Tanner, C. M. (1986) · Neurology · doi:10.1212/wnl.36.1.73 · Cited by 192 · cited 1×
“The same may apply for signs of autonomic dysfunctions, which also are reported to precede the symptoms of impaired somato-motor functions [42,52,56].”
BackgroundProblems of the Keimbahn. New work on mammalian germ cell lineage.
Sturrock, R. R. (1983) · PubMed · Cited by 182
Braak, H., Rüb, U., Sandmann-Keil, D., Gai, W. P., de Vos, R. A. I., Jansen Steur, E. N. H., Arai, K., & Braak, E. (2000) · Acta Neuropathologica · doi:10.1007/s004010051150 · Cited by 163 · cited 5×
“Cases with severe damage usually show lesions reaching the neocortex [10,13,22,23,50,53,63].”
BackgroundInfluentialSelf-citationDiseases of the Nervous System: Clinical Neurobiology.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-505_14 · Cited by 162
Is Parkinson's disease a primary olfactory disorder?
Hawkes, C. H. (1999) · QJM · doi:10.1093/qjmed/92.8.473 · Cited by 152
Immunoreactivity profile of hippocampal CA2/3 neurites in diffuse Lewy body disease
Dickson, D. W., Schmidt, M. L., Lee, V. M. Y., Zhao, M., Yen, S. H., & Trojanowski, J. Q. (1994) · Acta Neuropathologica · doi:10.1007/bf00296742 · Cited by 147 · cited 1×
“The plexus of long LNs extending throughout the second sector of the Ammon’s horn [26,27] generally begins developing at stage 3 (Fig.”
BackgroundRüb, U., Tredici, K. D., Schultz, C., Ghebremedhin, E., de Vos, R. A. I., Steur, E. N. H. J., & Braak, H. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00269-x · Cited by 137 · cited 3×
“This was followed by standard pretreatment with formic acid prior to incubation for 18 h in the affinity-purified -synuclein antiserum (AFshp) at a dilution of 1:2000–4000 [ 63 ].”
BackgroundMethodInfluentialSelf-citationPrice, J. L. (1990) · Elsevier eBooks · doi:10.1016/b978-0-12-547625-6.50034-9 · Cited by 137
Gai, W. P., Power, J. H., Blumbergs, P. C., Culvenor, J. G., & Jensen, P. H. (1999) · PubMed · Cited by 136
(1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.02093.x · Cited by 122 · cited 1×
“Gai (Flinders Medical Centre, Australia) in sheep using a peptide corresponding to the amino acid residues 116–131 of the human -synuclein [34].”
BackgroundRelationships between Lewy bodies and pale bodies in Parkinson's disease
Dale, G. E., Probst, A., Luthert, P., Martin, J., Anderton, B. H., & Leigh, P. N. (1992) · Acta Neuropathologica · doi:10.1007/bf00310030 · Cited by 114
Neuronal inclusions of Parkinson's disease
Gibb, W. R. G., Scott, T., & Lees, A. J. (1991) · Movement Disorders · doi:10.1002/mds.870060103 · Cited by 103 · cited 1×
“At times, ill-defined and weakly immunopositive “pale bodies” [18,40,49] appear between the pigment deposit and the cell nucleus or adjacent to a LB (Fig.”
BackgroundWhen does Parkinson's disease begin?
Wc, K. (1992) · PubMed · Cited by 99
The significance of tau and α-synuclein inclusions in neurodegenerative diseases
Goedert, M. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00200-8 · Cited by 95 · cited 3×
“The induction sites and cell types involved in multiple system atrophy or Hallervorden–Spatz disease differ from those affected in PD [35, 41 ].”
BackgroundInfluentialEvent-related brain potentials to attended and ignored olfactory and trigeminal stimuli
Geisler, M. W., & Murphy, C. (2000) · International Journal of Psychophysiology · doi:10.1016/s0167-8760(00)00111-2 · Cited by 94 · cited 1×
“Given the existence of advanced techniques for reliable measurement of olfactory performance, it does not appear inappropriate to use impairments in olfaction as one of the markers for early phases of PD [36,64].”
BackgroundPerry, R. H., Irving, D., & Tomlinson, B. E. (1990) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(90)90037-n · Cited by 94 · cited 1×
“Cases from specialized clinics for neurological or psychiatric diseases were excluded from the screening procedure [ 59 ].”
MethodPreclinical (premotor) Parkinson’s disease
Wolters, E. C., Francot, C. M. J. E., Bergmans, P., Winogrodzka, A., Booij, J., Berendse, H. W., & Stoof, J. C. (2000) · Journal of Neurology · doi:10.1007/pl00022910 · Cited by 90 · cited 1×
“According to some clinical studies, PD-patients frequently complain of an impaired sense of smell years prior to the appearance of somato-motor impairments [45,46,57,71].”
BackgroundTau and Synuclein and Their Role in Neuropathology
Dickson, D. W. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00548.x · Cited by 88 · cited 1×
“for the non-lysosomal ATP-dependent breakdown of abnormal proteins, gradually transforms into virtually insoluble LNs or LBs [1,2,15,25,29,41,49,67,70].”
BackgroundAutonomic nervous system disturbances in Parkinson's disease.
Korczyn, A. D. (1990) · PubMed · Cited by 80
New Neuropathological Criteria for Alzheimer Disease
Hyman, B. T. (1998) · Archives of Neurology · doi:10.1001/archneur.55.9.1174 · Cited by 77 · cited 1×
“The severity of co-occurring AD-related pathology was classified according to a procedure permitting differentiation of stages I–VI in the development of neurofibrillary changes and stages A–C in the evolution of -amyloid deposits (Table 2) [6, 48 ].”
Methodde Vos, R. A. I., Jansen, E. N. H., Stam, F. C., Ravid, R., & Swaab, D. F. (1995) · Clinical Neurology and Neurosurgery · doi:10.1016/0303-8467(94)00060-j · Cited by 75 · cited 1×
“Cases with severe damage usually show lesions reaching the neocortex [10,13,22,23,50,53,63].”
BackgroundNeuropathology of dementing disorders
Markesbery, W. R. (1998) · Cited by 73
Nuclear configuration and neuronal types of the nucleus niger in the brain of the human adult.
Braak, H., & Braak, E. (1986) · PubMed · Cited by 69
Self-citationWakabayashi, K., Hansen, L. A., & Masliah, E. (1995) · Acta Neuropathologica · doi:10.1007/bf00307643 · Cited by 66 · cited 1×
“The outer cellular layers of this part of the cortex develop a network of filiform LNs while the inner ones show spherical LBs within small to medium-sized pyramidal neurons [ 69 ] (Fig. 3f).”
BackgroundNeuropathology of the Substantia nigra
Gibb, W. R. G. (2008) · European Neurology · doi:10.1159/000116721 · Cited by 66 · cited 1×
“Damage to specific subnuclei of the substantia nigra, pars compacta, with severe obliteration of their neuromelaninladen projection neurons, frequently is considered to be the most important hallmark of PD [20,31,38,39,43].”
BackgroundCardiovascular reflexes and autonomic dysfunction in parkinson's disease
Meco, G., Pratesi, L., & Bonifati, V. (1991) · Journal of Neurology · doi:10.1007/bf00314779 · Cited by 62 · cited 1×
“The same may apply for signs of autonomic dysfunctions, which also are reported to precede the symptoms of impaired somato-motor functions [42,52,56].”
BackgroundThe audiospinal reaction in parkinsonian patients reflects functional changes in reticular nuclei
Delwaide, P. J., Pepin, J. L., & de Noordhout, A. M. (1993) · Annals of Neurology · doi:10.1002/ana.410330111 · Cited by 59 · cited 1×
“Diagnostic tools designed to detect impaired functions of the gain setting system might be suitable markers for early phases of PD [13,21,55,68].”
BackgroundWakabayashi, K., Takahashi, H., Obata, K., & Ikuta, F. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90923-u · Cited by 57 · cited 1×
“for the non-lysosomal ATP-dependent breakdown of abnormal proteins, gradually transforms into virtually insoluble LNs or LBs [1,2,15,25,29,41,49,67,70].”
BackgroundNeurophysiological characterization of parkinsonian syndromes
Valls‐Solé, J. (2000) · Neurophysiologie Clinique · doi:10.1016/s0987-7053(00)00236-7 · Cited by 55 · cited 1×
“Diagnostic tools designed to detect impaired functions of the gain setting system might be suitable markers for early phases of PD [13,21,55,68].”
BackgroundPathological Changes in the Parahippocampal Region in Select Non‐Alzheimer's Dementias
BRAAK, H., DEL TREDICI, K., BOHL, J., BRATZKE, H., & BRAAK, E. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06729.x · Cited by 52 · cited 1×
“The damage incurred by important limbic structures (amygdala, hippocampal formation, anteromedial temporal mesocortex) as well as by extensive neocortical territories during stages 5–6 might well be considered to pave the way for declining intellectual faculties [ 14 ] and, in fact, impaired cognition is a frequent ph…”
BackgroundSelf-citationThe detection of preclinical Parkinson's disease: What is the role of positron emission tomography?
Sawle, G. V. (1993) · Movement Disorders · doi:10.1002/mds.870080304 · Cited by 42 · cited 1×
“It has been reported that non-motor symptoms usually antedate the PD-associated somato-motor dysfunctions by many years [51,66].”
BackgroundSandmann-Keil, D., Braak, H., Okochi, M., Haass, C., & Braak, E. (1999) · Acta Neuropathologica · doi:10.1007/s004010051110 · Cited by 41 · cited 1×
“The Campbell–Switzer silver-pyridine technique was applied for detection of LBs and LNs as well as AD-associated amyloid deposits and neuromelanin [3,65].”
MethodSelf-citationBraak, E., & Braak, H. (1999) · Journal of Neuroscience Methods · doi:10.1016/s0165-0270(98)00173-3 · Cited by 37 · cited 1×
“The Campbell–Switzer silver-pyridine technique was applied for detection of LBs and LNs as well as AD-associated amyloid deposits and neuromelanin [3,65].”
MethodSelf-citationOlfactory evoked potentials in Parkinson's disease, Alzheimer's disease and anosmic patients
Sakuma, K., Nakashima, K., & Takahashi, K. (1996) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.1996.tb01660.x · Cited by 34 · cited 1×
“Given the existence of advanced techniques for reliable measurement of olfactory performance, it does not appear inappropriate to use impairments in olfaction as one of the markers for early phases of PD [36,64].”
BackgroundBraak, H., Tredici, K. D., Gai, W., & Braak, E. (2000) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(00)00101-0 · Cited by 27 · cited 1×
“for the non-lysosomal ATP-dependent breakdown of abnormal proteins, gradually transforms into virtually insoluble LNs or LBs [1,2,15,25,29,41,49,67,70].”
BackgroundSelf-citationLozza, A., Pepin, J. L., Rapisarda, G., Moglia, A., & Delwaide, P. J. (1997) · Journal of Neural Transmission · doi:10.1007/bf01291885 · Cited by 21 · cited 1×
“Diagnostic tools designed to detect impaired functions of the gain setting system might be suitable markers for early phases of PD [13,21, 55 ,68].”
BackgroundPathological and clinical features of Parkinson's disease with and without dementia
de Vos, R. A. I., Jansen, E. N. H., Yilmazer‐Hanke, D., Braak, H., & Braak, E. (1996) · Cambridge University Press eBooks · doi:10.1017/cbo9780511601187.026 · Cited by 9
Self-citationBergeron, C., & Pollanen, M. S. (1996) · Cambridge University Press eBooks · doi:10.1017/cbo9780511601187.029 · Cited by 5
Research works printed but not linked: 7
- Braak H. Architectonics as seen by lipofuscin stains. In: Jones EG, Peters A, editors. Cerebral cortex. Cellular components of the cerebral cortex, vol. 1. London: Plenum Press, 1984. p. 59–104.
- Braak H, Braak E, Yilmazer D, Schultz C, Bohl J. Age-related changes of the human cerebral cortex. In: Cruz-Sanchez FF, Ravid R, Cuzner ML, editors. Neuropathological diagnostic criteria for brain banking. Biomedical health research, vol. 10. Amsterdam: IOS Press 1995;19:14–9.
- Fearnley J, Lees AJ. Pathology of Parkinson’s disease. In: Calne DB, editor. Neurodegenerative diseases. Philadelphia: Saunders, 1991. p. 545–54.
- Hassler, 1937, Zur Normalanatomie der Substantia nigra. Versuch einer architektonischen Gliederung, J. Psychol. Neurol., 48, 1
- Hassler, 1938, Zur Pathologie der paralysis agitans und des postencephalitischen Parkinsonismus, J. Psychol. Neurol., 48, 387
- Lowe J. Lewy bodies. In: Calne DB, editor. Neurodegenerative diseases. Philadelphia: Saunders, 1994. p. 51–69.
- Rajput AH. Clinical features and natural history of Parkinson’s disease (special consideration of aging). In: Calne DB, editor. Neurodegenerative diseases. Philadelphia: Saunders, 1994. p. 555–71.
Cited by
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
Bloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920
Metadata
- Authors
- Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E.
- Affiliations
- Goethe University Frankfurt (DE)
- Corresponding author
- Braak, Heiko
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2003-03
- Volume
- 24
- Issue
- 2
- Pages
- 197-211
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W2073449985
- Cited by
- 10,777
- References
- 71
- Citations by year
- 2026: 569 · 2025: 700 · 2024: 735 · 2023: 626 · 2022: 749 · 2021: 731 · 2020: 724 · 2019: 594 · 2018: 547 · 2017: 551 · 2016: 475 · 2015: 493 · 2014: 450 · 2013: 485 · 2012: 403
- FWCI
- 45.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Neurobiology of Aging (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- National Health and Medical Research Council
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Parkinson's disease, neuropathology, alpha-synuclein, Lewy bodies, Lewy neurites, dorsal motor nucleus of the vagus, anterior olfactory nucleus, brainstem, cortical involvement, prefrontal cortex, neuropathological diagnosis
- MeSH terms
- Aged, Aged, 80 and over, Brain, Female, Humans, Male, Medulla Oblongata, Parkinson Disease, Temporal Lobe, Lewy Bodies, Neocortex, Lewy Body Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.